BI 14332

Drug Profile

BI 14332

Alternative Names: BI-14332-CL; BI14332

Latest Information Update: 14 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antihyperglycaemics; Piperidines; Pyridines; Xanthines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Aug 2014 Discontinued - Phase-I for Type-2 diabetes mellitus in Germany (PO)
  • 30 Nov 2006 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02212938)
  • 30 Nov 2006 Boehringer Ingelheim initiates enrolment in a phase I trial for Type-2 diabetes mellitus in Germany (NCT02212925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top